問題 › 販売サイクルが長すぎる › HealthTech & Digital Health
サイクルが長い原因は、運用担当者が測定期間後のリスク負担シェア維持をCFOに示せていないことであり、販売担当者が製品説明に失敗しているわけではありません。 デジタルヘルス企業でこれが難しい理由は構造的です。成果リスクの負担を、企業がその負担を担えるかどうかを確認できる前に契約してしまうためです。測定期間12ヶ月に対し販売サイクル11ヶ月という状況では、社内分析が止まりやすいポイントにリスク負担シェアとエンゲージメント率を同時に置く必要があります。
サイクルが長い原因は、運用担当者が測定期間後のリスク負担シェア維持をCFOに示せていないことであり、販売担当者が製品説明に失敗しているわけではありません。 デジタルヘルス企業でこれが難しい理由は構造的です。成果リスクの負担を、企業がその負担を担えるかどうかを確認できる前に契約してしまうためです。測定期間12ヶ月に対し販売サイクル11ヶ月という状況では、社内分析が止まりやすいポイントにリスク負担シェアとエンゲージメント率を同時に置く必要があります。
サイクルが長引くのは、プラットフォームへの関心が薄れたからではありません。運用担当者がCFOやCEOに対し、これまでに集めたエンゲージメント率と成果データだけでリスク負担シェアを正当化しなければならない段階で停滞しています。
ここから解決策が変わります。サイクル短縮は主に、チャンピオンにPMPM、 engagement rate低下時の粗利圧縮リスク、成果帰属とロゴ流出の比較をCFOに持ち帰るための材料を与えることです。
もう一つの原因は、臨床または運用担当者に販売し、リスク負担シェアを承認できない相手を選んでいることです。この場合、目に見えるサイクルは長くなりませんが、最後にCFO確認待ちの隠れた期間が加わります。
この3つが揃うと特徴的です。1つだけでは別のことを示すことが多いです。
✓ パイロット後にエンゲージメント率データをリスク負担シェアモデルへ変換する段階で案件が停滞する
✓ CFOがPMPMと粗利見通しを確認する間に、同一案件の予測日程が繰り返し後ろ倒しになる
✓ 失注案件での主な競合は「決定しない」ことで、登録会員ベースでのロゴ流出として現れる
通常、事態を悪化させる対応です。 フォローアップ活動を増やすことです。成果帰属やPMPMに関する新しい材料を渡さず、チャンピオンへの圧力だけが高まります。
It is for you if you run or finance a digital health company and deals consistently stall at the same stage. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on デジタルヘルス企業. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Monetize the largest three-condition outcomes dataset to subsidize outcomes risk and generate 13% growth without increasing at-risk share.
The leak it closes. Reduces dependence on 38% at-risk PMPM revenue by adding non-at-risk, high-margin revenue stream
The assumption it rests on. State privacy laws do not mandate patient-level consent for de-identified data before 2029 — the engine put the probability at 0.7.
| Investment required | $1.8–2.4M over 18 months |
| Expected return | 2.3–3.8× on $2.1M midpoint investment within 36 months |
| Revenue, year 1 | $0.8–1.2M ARR (3–4 deals) |
| Revenue, year 2 | $2.4–3.6M ARR (9–12 deals) |
| Revenue, year 3 | $4.2–6.8M ARR (15–20 deals) |
| Exit criteria | Kill move if fewer than 2 deals ≥$150k ACV close by Month 12 OR if any state privacy statute requiring patient-level consent for de-identified data is enacted before Month 18; reallocate remaining budget to Clinical Coaching Capacity Marketplace node |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market & Commercial Strategy, one of 29 engagements the platform runs. For デジタルヘルス企業 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 完全なレポートはこちらをご覧ください if you would rather see the depth first.
案件が最も長く留まる段階を探し、その段階でバイヤーが何をしなければならないかを確認します。ほぼ必ず内部承認であり、必要なのは説得ではなく資料です。
最後の段階を短縮するだけで、時間のかかっている前段の停滞には影響しません。また、待てば値引きされるとバイヤーに学習させます。
いいえ。案件規模と勝率がそれを正当化する場合は問題ではありません。キャッシュコンバージョンに許容される期間を超えたときに問題となります。これは販売ではなく資金調達の制約です。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית